| 摘要: |
| 目的 评价连翘苷元(PHI)不同制剂在大鼠体内的药代动力学行为,探讨纳米晶制剂对口服生物利用度的改善作用。方法 将15只SD大鼠分为3组,分别静脉注射PHI注射液(5 mg·kg-1)或灌胃PHI粗混悬液、PHI纳米晶(100 mg·kg-1)。于给药后多个时间点采血,采用超高效液相色谱串联质谱(UPLC-MS/MS)法测定血药浓度,利用DAS 2.0计算药动学参数及绝对生物利用度,并进行组间比较。结果 静脉注射PHI后血药浓度迅速达峰并快速下降;与粗混悬液组相比,PHI纳米晶组的AUC0-∞、Cmax均升高(P<0.05),Tmax提前,表观清除率CLz/F降低(P<0.05),t1/2z差异无统计学意义。绝对生物利用度由粗混悬液的1.20%提升至13.06%(P<0.01)。结论 PHI纳米晶制剂能提高口服吸收速率与生物利用度,改善药动学特性,为其作为抗纤维化口服制剂的开发提供实验依据。 |
| 关键词: 连翘苷元 纳米晶 药代动力学 超高效液相色谱串联质谱 生物利用度 大鼠 |
| DOI:10.13506/j.cnki.jpr.2026.06.007 |
| 基金项目: |
|
收稿日期:2026-01-30
修回日期:2026-04-07
|
|
| Pharmacokinetics and bioavailability of phillygenin nanocrystalline formulation in rats |
| LIU Xiaohua1,YAO Jingchun2,GAO Ruizhi1,CUI Hanwen1,FAN Jianwei3,YANG Mei3,4,WEI Yongjia1 |
| (1. Heilongjiang Provincial Hospital, Harbin 150036, China;2. Lunan Pharmaceutical Group New Drug Pharmacology Center, Linyi 273499,China;3. State Key Laboratory of Integration and Innovation of Classic Formula and Modern Chinese Medicine, Lunan Pharmaceutical Group Co., Ltd., Linyi 276006, China;4.Lunan Houpu Pharmaceutical Co., Ltd., Linyi 276005,China) |
| Abstract: |
| Objective To evaluate the pharmacokinetic behavior of different Phillygenin (PHI) formulations in rats and investigate the improvement in oral bioavailability by its nanocrystalline formulation. Methods Fifteen Sprague-Dawley rats were divided into three groups, receiving either an intravenous injection of PHI solution (5 mg·kg-1) or oral administration of a coarse PHI suspension or PHI nanocrystals (both at 100 mg·kg-1). Blood samples were collected at multiple time points post-dose. Plasma PHI concentrations were determined by UPLC-MS/MS, and pharmacokinetic parameters along with absolute bioavailability were calculated using DAS 2.0 software. And group comparisons were performed. Results Following intravenous administration, plasma PHI concentration peaked rapidly and declined quickly. Compared with the coarse suspension group, the PHI nanocrystal group showed significantly increased AUC0-∞ and Cmax(P<0.05), significantly shortened Tmax, and significantly decreased apparent clearance CLz/F (P<0.05), while no significant difference was observed in t1/2z. The absolute bioavailability was significantly increased from 1.20% for the coarse suspension to 13.06% for the nanocrystals (P<0.01). Conclusion The PHI nanocrystalline formulation significantly improves the oral absorption rate, bioavailability, and pharmacokinetic profile. These findings provide an experimental basis for its development as an oral anti-fibrotic agent. |
| Key words: Forsythia glycosides Nanocrystals pharmacokinetics UPLC-MS/MS Bioavailability Rats |